-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

365 Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Program: Oral and Poster Abstracts
Type: Oral
Session: 904. Outcomes Research - Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia
Hematology Disease Topics & Pathways:
sickle cell disease, Biological, Diseases, Therapies, Hemoglobinopathies, gene therapy
Sunday, December 6, 2020: 9:45 AM

Julie Kanter, MD1, John F. Tisdale, MD2,3, Markus Y Mapara, MD, PhD4, Janet L. Kwiatkowski, MD, MSCE5,6, Lakshmanan Krishnamurti, MD7, Ren Chen8*, Meghan E. Gallagher, MSc8*, Yuchen Ding, PhD8*, Sunita Goyal, MD8*, Clark Paramore, MPH8*, Alexis A. Thompson, MD9,10 and Mark C. Walters, MD11

1University of Alabama at Birmingham, Birmingham, AL
2National Institutes of Health, Bethesda, MD
3Clinical and Molecular Therapeutics Branch, NHLBI / NIDDK, NIH, Bethesda, MD
4Columbia Center for Translational Immunology, Columbia University, New York, NY
5University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
6The Children's Hospital of Philadelphia, Philadelphia, PA
7Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA
8bluebird bio, Inc., Cambridge, MA
9Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
10Northwestern University Feinberg School of Medicine, Chicago, IL
11UCSF Benioff Children's Hospital Oakland, Oakland, CA


In patients with sickle cell disease (SCD), health-related quality of life (HRQoL) is worse than in the general population and comparable or worse than in patients with other chronic or painful diseases such as cystic fibrosis or cancer. Targeting SCD pathophysiology may significantly improve HRQoL in addition to clinical outcomes. In the ongoing phase 1/2 HGB-206 Study (NCT02140554), which evaluates the safety and efficacy of LentiGlobin for SCD (bb1111) gene therapy (GT), the most recently treated cohort of patients (Group C) have demonstrated improvements in laboratory assessments, including a trend toward normalization in key hemolysis markers and improvements in total hemoglobin values, and near resolution of vaso-occlusive crises and acute chest syndrome (ACS), suggesting a fundamental effect on sickle cell pathophysiology. Patient-reported HRQoL outcomes through 12 months post-treatment are presented here.


Patients (≥12 and ≤50 years of age) with SCD and history of stroke or severe vaso-occlusive events, including acute episodes of pain and ACS, were enrolled. CD34+ cells collected by plerixafor mobilization/apheresis were transduced with BB305 lentiviral vector. LentiGlobin was infused following myeloablative busulfan conditioning. In addition to laboratory and clinical assessments, patients were monitored for patient-reported outcomes (PROs) using the PRO Measurement Information System (PROMIS)-57. PROMIS-57 assesses HRQoL using collection of short forms containing 8 questions for each of the 7 PROMIS domains (Depression, Anxiety, Pain Interference, Fatigue, Sleep Disturbance, in which a lower score denotes improvement, and Physical Function, Satisfaction with Participation in Social Roles, in which a higher score denotes improvement) and a 0–10 Pain Intensity numeric rating scale (NRS). PROMIS-57 has been validated in patients with SCD.

Data were analyzed for ten Group C patients who had at least 12 months of follow-up and had completed PROMIS-57 assessments as of March 3, 2020. For each domain, patients were stratified into 2 sub-groups based on baseline scores and population norm (i.e., baseline scores “better” than or near the population norm and baseline scores “worse” than the population norm). The stratification was built upon the premise that patients with baseline scores “better” or near the population norm would not be expected to improve. The US general population norm was 2.6 for Pain Intensity and a T-score of 50 for all other domains. The minimal clinically importance difference (2-point difference for pain intensity NRS and 5-point difference for other domains) was selected based on the PROMIS guidelines and literature.


Patients who had baseline scores “worse” than the population norm reported improvements in all domains at Month 6, which were sustained through Month 12. These patients reported clinically meaningful improvement in 6/8 domains; mean T-scores at baseline and Month 12 were 6 and 2.4 for Pain Intensity (n=5); 63 and 48 for Pain Interference (n=7); 62 and 48 for Anxiety (n=3); 62 and 44 for Depression (n=4); 39 and 60 for Satisfaction with Social Roles (n=5); and 40 and 56 for Physical Function (n=4), respectively. Only 1 patient was included in the analysis of Fatigue and Sleep Disturbance domains, thereby limiting the conclusions in these 2 domains (Figure 1).

Patients who had baseline scores that were “better” than or near than the population norm reported clinically meaningful improvements in the Physical Function (n=6) and Fatigue domains (n=9); mean scores at baseline and Month 12 were 49 and 55 for Physical Function and 50 and 43 for Fatigue, respectively. Among patients in this sub-group, Pain Intensity (n=5) and Pain Interference (n=3) scores were stable from Month 6 through Month 12; there was no clinically meaningful change for the Anxiety (n=7) and Depression (n=6) domains, however, worsening was observed in the Satisfaction with Social Role (n=4) and Sleep Disturbance (n=9) domains (Figure 1).


LentiGlobin for SCD GT improved HRQoL in all domains of PROMIS-57 for patients whose baseline scores were “worse” than the population norm, including clinically meaningful improvements in all evaluable (6/8) domains. Larger sample sizes are required to clarify the impact of LentiGlobin for SCD for some PROMIS-57 domains.

Disclosures: Kanter: Sanofi: Consultancy; Medscape: Honoraria; Novartis: Consultancy; bluebird bio, inc: Consultancy, Honoraria; BEAM: Membership on an entity's Board of Directors or advisory committees; AGIOS: Membership on an entity's Board of Directors or advisory committees; SCDAA Medical and Research Advisory Board: Membership on an entity's Board of Directors or advisory committees; Guidepoint Global: Honoraria; GLG: Honoraria; Jeffries: Honoraria; Cowen: Honoraria; Wells Fargo: Honoraria; NHLBI Sickle Cell Advisory Board: Membership on an entity's Board of Directors or advisory committees. Kwiatkowski: Terumo Corp: Research Funding; Imara: Consultancy; Celgene: Consultancy; Agios: Consultancy; bluebird bio, Inc.: Consultancy, Research Funding; Novartis: Research Funding; Sangamo: Research Funding; Apopharma: Research Funding; Bristol Myers Squibb: Consultancy. Chen: bluebird bio, Inc.: Consultancy. Gallagher: bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Ding: bluebird bio, Inc.: Current Employment, Other: Salary. Goyal: bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Paramore: bluebird bio, Inc.: Current Employment, Other: Ownership Interest and Salary. Thompson: Beam: Consultancy; bluebird bio, Inc.: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Agios: Consultancy; Baxalta: Research Funding; Biomarin: Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Walters: AllCells, Inc: Consultancy; Veevo Biomedicine: Consultancy; Editas: Consultancy.

*signifies non-member of ASH